Sugi Predict

Sugi Predict / Compounds / SCHEMBL1008715

SCHEMBL1008715

SCHEMBL1008715

O=C(O)C(CC1CCOCC1)n1ncc(Oc2ccccc2Cl)cc1=O

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LPAR1 Q92633 1/20 0.37
▸ LPAR5 Q9H1C0 1/20 0.37
▸ ABL1 P00519 1/20 0.37
▸ GCK P35557 5/20 0.36
▸ FFAR2 O15552 1/20 0.36
▸ F11 P03951 1/20 0.35
▸ KLKB1 P03952 1/20 0.35
▸ KDM4C Q9H3R0 1/20 0.34
▸ LDHA P00338 2/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ AKT1 P31749 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ TTK P33981 1/20 0.34
▸ PDE9A O76083 1/20 0.34
▸ SCD O00767 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008300 0.85 GCK (0.36) LPAR1LPAR5GCKFFAR2F11
SCHEMBL1008584 0.85 HIF1A (0.36) GCKKDM4CALDH1A1KMT2A
SCHEMBL1008556 0.82 HIF1A (0.37) GCKF11
SCHEMBL1008521 0.82 GCK (0.38) LPAR1LPAR5GCKPDE9A
SCHEMBL1008904 0.82 ADRA1D (0.41) ALDH1A1SMN1; SMN2KMT2A
SCHEMBL1064688 0.80 GCK (0.48) GCKF11KLKB1
SCHEMBL1063782 0.80 GCK (0.48) GCKF11KLKB1
SCHEMBL1063780 0.80 GCK (0.48) GCKF11KLKB1
SCHEMBL1008741 0.80 LPAR1 (0.39) LPAR1LPAR5F11ALDH1A1HPGD
SCHEMBL1008265 0.80 FFAR1 (0.40) ALDH1A1SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 — — EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK LPAR1 4693/4885LPAR5 4405/4885ABL1 3470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.